This is a real-world medical entrance exam question, please give the true answer based on the question and selection. Topic name: Hematology, Subject name: Pharmacology
[{'content': 'Which of the following is a recently approved monoclonal antibody for treatment of Hemophilia A? \nSelect and explain. \nA. Emicizumab, B. Sarilumab, C. Abaloparatide, D. Durvalumab', 'role': 'user'}, {'content': 'Answer: A \nExplanation: EMICIZUMAB : Bispecific monoclonal antibody. Binds to both activated factors IX and X and helps in activation of factor X. This is normally the function of coagulation factor VIII, which is missing in haemophilia A patients Act like factor VIII so it is used for HEMOPHILIA A patients. SARILUMAB : MAB against IL -6 Used for Rheumatic ahritis ABALOPARATIDE : It is parathyroid related protein Used for Osteoporosis Injectable drug DURVALUMAB : MAB against PD ligand Used for urothelial carcinoma.', 'role': 'assistant'}]